Instil Bio, Inc.
TIL Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$5.84
KIRA · Stoqly’s AI analyst, in plain words
- Instil Bio, Inc. lost $71.4M in fiscal 2025.
Market cap
$39.6M
P/E
—
Revenue
—
Net income
−$71.4M
Free cash flow
—
Operating margin
—
Instil Bio, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$71.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Instil Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- Instil Bio, Inc.
- CIK
- 0001789769
Instil Bio, Inc. · TIL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | — | — | — | — |
| Revenue growth | −100.0% | — | — | — | — |
| Net income | −$157M | −$223M | −$156M | −$74.1M | −$71.4M |
| Diluted EPS | −$1.48 | −$34.46 | −$24.00 | −$11.39 | −$10.70 |
| Cash | |||||
| Cash from operations | −$122M | −$180M | −$82.0M | −$55.7M | −$36.6M |
| Capital expenditure | $57.8M | $84.6M | $20.7M | $0.0M | — |
| Free cash flow | −$180M | −$265M | −$103M | −$55.7M | — |
| Share count change | 562.5% | −93.9% | 0.4% | 0.1% | 2.4% |
| Debt and strength | |||||
| Cash and short-term investments | $454M | $261M | $150M | $8.8M | $6.6M |
| Shareholders' equity | $555M | $364M | $226M | $169M | $114M |
| Current ratio | 11.2x | 8.2x | 15.2x | 15.8x | 39.5x |
| Interest coverage | — | −120.3x | −30.6x | −8.2x | −13.5x |
| Returns and quality | |||||
| Return on equity | −60.8% | −48.6% | −53.0% | −37.5% | −50.4% |
| Return on tangible equity | −28.5% | −61.4% | −69.1% | −43.8% | −62.7% |
| Piotroski F-score | 1 | — | — | — | — |
| Altman Z'' | 12.4 | 0.4 | −3.7 | −5.2 | −6.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Instil Bio, Inc. · TIL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.84 a share, the company is worth $39.6M.
Source: SEC EDGAR XBRL filings (CIK 0001789769). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.